328 related articles for article (PubMed ID: 23833051)
1. Challenges and controversies in the diagnosis of malignant mesothelioma: Part 2. Malignant mesothelioma subtypes, pleural synovial sarcoma, molecular and prognostic aspects of mesothelioma, BAP1, aquaporin-1 and microRNA.
Henderson DW; Reid G; Kao SC; van Zandwijk N; Klebe S
J Clin Pathol; 2013 Oct; 66(10):854-61. PubMed ID: 23833051
[TBL] [Abstract][Full Text] [Related]
2. BAP1 facilitates diagnostic objectivity, classification, and prognostication in malignant pleural mesothelioma.
McGregor SM; Dunning R; Hyjek E; Vigneswaran W; Husain AN; Krausz T
Hum Pathol; 2015 Nov; 46(11):1670-8. PubMed ID: 26376834
[TBL] [Abstract][Full Text] [Related]
3. A combination of MTAP and BAP1 immunohistochemistry is effective for distinguishing sarcomatoid mesothelioma from fibrous pleuritis.
Kinoshita Y; Hamasaki M; Yoshimura M; Matsumoto S; Sato A; Tsujimura T; Ueda H; Makihata S; Kato F; Iwasaki A; Nabeshima K
Lung Cancer; 2018 Nov; 125():198-204. PubMed ID: 30429020
[TBL] [Abstract][Full Text] [Related]
4. Usefulness of p16/CDKN2A fluorescence in situ hybridization and BAP1 immunohistochemistry for the diagnosis of biphasic mesothelioma.
Wu D; Hiroshima K; Yusa T; Ozaki D; Koh E; Sekine Y; Matsumoto S; Nabeshima K; Sato A; Tsujimura T; Yamakawa H; Tada Y; Shimada H; Tagawa M
Ann Diagn Pathol; 2017 Feb; 26():31-37. PubMed ID: 28038708
[TBL] [Abstract][Full Text] [Related]
5. [Loss of BRCA associated protein 1 expression in malignant mesothelioma and its diagnostic application].
Guo ZY; Sun WY; Michele Y; Zhang JL; Hu D; Su HN; Yang WM; Mao W
Zhonghua Bing Li Xue Za Zhi; 2017 Oct; 46(10):699-703. PubMed ID: 29050072
[No Abstract] [Full Text] [Related]
6. BRCA1-Associated Protein 1 (BAP1) Immunohistochemical Expression as a Diagnostic Tool in Malignant Pleural Mesothelioma Classification: A Large Retrospective Study.
Righi L; Duregon E; Vatrano S; Izzo S; Giorcelli J; Rondón-Lagos M; Ascoli V; Ruffini E; Ventura L; Volante M; Papotti M; Scagliotti GV
J Thorac Oncol; 2016 Nov; 11(11):2006-2017. PubMed ID: 27422796
[TBL] [Abstract][Full Text] [Related]
7. Challenges and controversies in the diagnosis of mesothelioma: Part 1. Cytology-only diagnosis, biopsies, immunohistochemistry, discrimination between mesothelioma and reactive mesothelial hyperplasia, and biomarkers.
Henderson DW; Reid G; Kao SC; van Zandwijk N; Klebe S
J Clin Pathol; 2013 Oct; 66(10):847-53. PubMed ID: 23814259
[TBL] [Abstract][Full Text] [Related]
8. Pleural mesothelioma classification update.
Beasley MB; Galateau-Salle F; Dacic S
Virchows Arch; 2021 Jan; 478(1):59-72. PubMed ID: 33475835
[TBL] [Abstract][Full Text] [Related]
9. BAP1 Is Altered by Copy Number Loss, Mutation, and/or Loss of Protein Expression in More Than 70% of Malignant Peritoneal Mesotheliomas.
Leblay N; Leprêtre F; Le Stang N; Gautier-Stein A; Villeneuve L; Isaac S; Maillet D; Galateau-Sallé F; Villenet C; Sebda S; Goracci A; Byrnes G; McKay JD; Figeac M; Glehen O; Gilly FN; Foll M; Fernandez-Cuesta L; Brevet M
J Thorac Oncol; 2017 Apr; 12(4):724-733. PubMed ID: 28034829
[TBL] [Abstract][Full Text] [Related]
10. Value of D2-40 in the differential diagnosis of pleural neoplasms with emphasis on its positivity in solitary fibrous tumor.
Hu Y; Yang Q; McMahon LA; Wang HL; Xu H
Appl Immunohistochem Mol Morphol; 2010 Oct; 18(5):411-3. PubMed ID: 20436345
[TBL] [Abstract][Full Text] [Related]
11. Pleural neoplastic pathology.
Karpathiou G; Stefanou D; Froudarakis ME
Respir Med; 2015 Aug; 109(8):931-43. PubMed ID: 26048082
[TBL] [Abstract][Full Text] [Related]
12. Molecular analyses, morphology and immunohistochemistry together differentiate pleural synovial sarcomas from mesotheliomas: clinical implications.
Carbone M; Rizzo P; Powers A; Bocchetta M; Fresco R; Krausz T
Anticancer Res; 2002; 22(6B):3443-8. PubMed ID: 12552937
[TBL] [Abstract][Full Text] [Related]
13. Pleural malignant mesothelioma versus pleuropulmonary synovial sarcoma: a clinicopathological study of 22 cases with molecular analysis and survival data.
Klebe S; Prabhakaran S; Hocking A; Pulford E; Moore S; Nicola M; Allen PW; Henderson DW
Pathology; 2018 Oct; 50(6):629-634. PubMed ID: 30170702
[TBL] [Abstract][Full Text] [Related]
14. The potential utility of GATA binding protein 3 for diagnosis of malignant pleural mesotheliomas.
Prabhakaran S; Hocking A; Kim C; Hussey M; Klebe S
Hum Pathol; 2020 Nov; 105():1-8. PubMed ID: 32888937
[TBL] [Abstract][Full Text] [Related]
15. Diagnostic usefulness of p16/CDKN2A FISH in distinguishing between sarcomatoid mesothelioma and fibrous pleuritis.
Wu D; Hiroshima K; Matsumoto S; Nabeshima K; Yusa T; Ozaki D; Fujino M; Yamakawa H; Nakatani Y; Tada Y; Shimada H; Tagawa M
Am J Clin Pathol; 2013 Jan; 139(1):39-46. PubMed ID: 23270897
[TBL] [Abstract][Full Text] [Related]
16. Spindle cell tumors of the pleura: differential diagnosis.
Rdzanek M; Fresco R; Pass HI; Carbone M
Semin Diagn Pathol; 2006 Feb; 23(1):44-55. PubMed ID: 17044195
[TBL] [Abstract][Full Text] [Related]
17. Pleural mesothelioma classification-update and challenges.
Dacic S
Mod Pathol; 2022 Jan; 35(Suppl 1):51-56. PubMed ID: 34465883
[TBL] [Abstract][Full Text] [Related]
18. [BRCA1 associated protein 1 (BAP1) expression in pleural diffuse malignant mesothelioma: A comparative cytological and histological analyses on 50 patients].
Jaouen A; Thivolet-Bejui F; Chalabreysse L; Piaton E; Traverse-Glehen A; Isaac S; Decaussin-Petrucci M; Depaepe L; Fontaine J; Remy I; Maury JM; Brevet M
Ann Pathol; 2016 Apr; 36(2):111-9. PubMed ID: 26995100
[TBL] [Abstract][Full Text] [Related]
19. Malignant Mesothelioma, BAP1 Immunohistochemistry, and VEGFA: Does BAP1 Have Potential for Early Diagnosis and Assessment of Prognosis?
Pulford E; Huilgol K; Moffat D; Henderson DW; Klebe S
Dis Markers; 2017; 2017():1310478. PubMed ID: 29085180
[TBL] [Abstract][Full Text] [Related]
20. Pathohistological diagnosis and differential diagnosis.
Tischoff I; Neid M; Neumann V; Tannapfel A
Recent Results Cancer Res; 2011; 189():57-78. PubMed ID: 21479896
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]